Effect of alrestatin on arginine-induced secretion of glucagon and insulin in the rat.
Alrestatin, a lens aldose reductase inhibitor, decreased i.v. arginine-induced glucagon levels and augmented arginine-stimulated insulin release in the ether anesthetized rat. Alrestatin may then be useful in the treatment of diabetes mellitus, due to its actions on insulin and glucagon, and its capacity to delay the onset of sugar-induced cataracts in the rat.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001120:Arginine / Q000494:pharmacology*; D005934:Glucagon / Q000378:metabolism*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007546:Isoquinolines / Q000494:pharmacology*; D007908:Lens, Crystalline / Q000201:enzymology; D008297:Male; D051381:Rats; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*
D007328:Insulin; D007546:Isoquinolines; D005934:Glucagon; D001120:Arginine; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase